ersonal use only
Chairman's Presentation to Extraordinary General Meeting
Professor Bernard Tuch
29 November 2021
www.lctglobal.com
Safe Harbour Statement
This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results | |
only | to be materially different from any future results, performance or achievements expressed or implied by such statements. |
There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' | |
requirements regarding any one or more product candidates nor can there be any assurance that such product candidates | |
will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. | |
In particular, management's expectations regarding the approval and commercialization of the product candidates could be | |
use | affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and |
new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or | |
ersonal | maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and |
general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, | |
product candidates, financial results and business prospects. | |
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forward- looking statements contained in this document as a result of new information, future events or developments or otherwise.
ersonal use only
Where Proceeds of Raisings Will be Directed
ersonal use only
LCT's Cash Position Post Raisings
Financial ramifications of 2Q FY2021 raisings
- LCT to receive up to up to $7.3m (before costs) from 2Q FY2021 raisings
- Proforma cash position post raisings of $7.6 million
Where this additional capital will be directed
- Ongoing development of NTCELL treatment for Parkinson's disease
- Exploring the potential for treating other medical disorders with living cells
ASX:LCT | OTCQB: LVCLY | www.lctglobal.com | | LCTglobal |
ersonal use only
ASX:LCT | OTCQB: LVCLY | www.lctglobal.com | | LCTglobal |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Living Cell Technologies Limited published this content on 29 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 November 2021 02:59:04 UTC.